000			04199nam a22004935i 4500
001			978-1-4020-2922-6
003			DE-He213
005			20251006084449.0
007			cr nn 008mamaa
008			100715s2005 ne | s |||| 0|eng d
020			_a9781402029226
020			_a99781402029226
024	7		_a10.1007/978-1-4020-2922-6 _2doi
082	0	4	_a614.5999 _223
100	1		_aHainaut, Pierre. _eeditor.
245	1	0	_a25 Years of p53 Research _h[electronic resource] / _cedited by Pierre Hainaut, Klas G. Wiman.
264		1	_aDordrecht : _bSpringer Netherlands, _c2005.
300			_aXI, 446 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aThe First Twenty-Five Years of p53 Research -- Regulation of p53 DNA Binding -- 20 Years of DNA Damage Signaling to p53 -- Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX -- Regulation of the p53 Response by Cellular Growth and Survival Factors -- P53, Cell Cycle Arrest and Apoptosis -- P53 Has a Direct Pro-apoptotic Action at the Mitochondria -- Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor -- P53, P63, and P73: Internecine Relations? -- P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells -- P53: Gatekeeper, Caretaker or Both? -- Analysis of p53 Gene Alterations in Cancer: A Critical View -- Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection -- Prognostic and Predictive Value of TP53 Mutations in Human Cancer -- P53 Links Tumor Development to Cancer Therapy -- Novel p53-Based Therapies: Strategies and Future Prospects -- Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue -- Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy -- Novel Approaches to p53-Based Therapy: ONYX-015 -- p53 as Seen by an Outsider.
520			_aThe discovery of p53 in 1979 marks the beginning of a most fascinating era of modern cancer research and molecular biology, an era that is still in full swing and does not show any signs of ending in the foreseeable future. p53 has emerged as a key tumor suppressor and important target for novel cancer therapy. For around 10 years, p53 was considered an oncogene with somewhat unusual features. However, a major paradigm shift occurred around 1988-89 when exciting new findings demonstrated that normal (wild type) p53 could inhibit transformation of cells in culture and that the p53 gene was mutated in a large fraction of human tumors. In fact, p53 appeared to be the most frequently mutated gene in cancer cells. Subsequent work during the 1990's showed that p53 was a transcription factor that regulates many other genes, and that p53 can trigger apoptosis, the suicide program of the cell. This book, written by world-leading p53 researchers including many of those who have shaped the field over the past 25 years, provides unique insights into the progress of the p53 field and the prospects for better cancer diagnosis and therapy in the future. It should be of interest to everybody working in cancer research, clinical oncology, and molecular biology, and indeed to anybody interested in science, medicine, as well as in recent developments of the ideas and concepts of the molecular biology of cancer.
650		0	_aMEDICINE.
650		0	_aONCOLOGY.
650		0	_aIMMUNOLOGY.
650		0	_aLIFE SCIENCES.
650	1	4	_aBIOMEDICINE.
650	2	4	_aCANCER RESEARCH.
650	2	4	_aONCOLOGY.
650	2	4	_aMOLECULAR MEDICINE.
650	2	4	_aBIOMEDICINE GENERAL.
650	2	4	_aIMMUNOLOGY.
650	2	4	_aLIFE SCIENCES, GENERAL.
700	1		_aWiman, Klas G. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781402029202
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4020-2922-6 _zVer el texto completo en las instalaciones del CICY
912			_aZDB-2-SBL
942			_2ddc _cER
999			_c60284 _d60284